Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
<p><strong>Background</strong> We evaluated the use of baricitinib, a Janus kinase (JAK) 1/2 inhibitor, for the treatment of patients admitted to hospital because of COVID-19.</p> <p><strong>Methods</strong> This randomised, controlled, open-label platform...
Үндсэн зохиолчид: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Формат: | Internet publication |
Хэл сонгох: | English |
Хэвлэсэн: |
2022
|
Search Result 1